Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet

Topics

Medicine

Internal Medicine

Ophthalmology

Surgery

Radiology, Nuclear Medicine And Imaging

Show all topics

DOI

10.1016/s0140-6736(22)00010-1

Other Formats

PDF